Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Repaglinide

FDA-approved product (tablet, oral), marketed as Prandin, Repaglinide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Repaglinide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other blood glucose lowering drugs, excl. insulins
FDA pharmacologic class
Glinide FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Repaglinide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Repaglinide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

    NCT04530981 · start 2021-09-22

    Registered record
    Registry ID
    NCT04530981
    Conditions
    GIST - Gastrointestinal Stromal Tumor
    Interventions
    Ripretinib; Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-22
    Completion
    2024-07-29
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST - Gastrointestinal Stromal Tumor
    InterventionRipretinib; Repaglinide
    PhasePhase 1
    Registry statusCompleted

  • A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

    NCT04718740 · start 2021-06-25

    Registered record
    Registry ID
    NCT04718740
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    fluzoparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-25
    Completion
    2023-07-15
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    Interventionfluzoparib
    PhasePhase 1
    Registry statusCompleted

  • GLUcose Transport and REnalPROtection in Chronic Kidney Disease

    NCT05998837 · start 2021-04-13

    Registered record
    Registry ID
    NCT05998837
    Conditions
    Chronic Kidney Disease; Diabetes Mellitus, Type 2; Hypertension
    Interventions
    Dapagliflozin 10mg Tab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-04-13
    Completion
    2024-09-30
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Diabetes Mellitus, Type 2; Hypertension
    InterventionDapagliflozin 10mg Tab; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

    NCT05360537 · start 2021-04-01

    Registered record
    Registry ID
    NCT05360537
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Insulin Degludec / Liraglutide Injectable Product; Insulin Glargine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2022-04-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionInsulin Degludec / Liraglutide Injectable Product; Insulin Glargine
    PhasePhase 4
    Registry statusCompleted

  • A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

    NCT04457180 · start 2020-11-16

    Registered record
    Registry ID
    NCT04457180
    Conditions
    Advanced Solid Tumor
    Interventions
    Apatinib Mesylate; Repaglinide; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-16
    Completion
    2021-06-19
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionApatinib Mesylate; Repaglinide; Bupropion
    PhasePhase 1
    Registry statusCompleted

  • Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

    NCT04664725 · start 2020-06-01

    Registered record
    Registry ID
    NCT04664725
    Conditions
    Prostate Cancer Patients
    Interventions
    Repaglinide, Bupropion and SHR3680
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2020-06-01
    Completion
    2021-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Patients
    InterventionRepaglinide, Bupropion and SHR3680
    PhasePhase 1
    Registry statusUnknown

  • Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    NCT03947385 · start 2019-06-28

    Registered record
    Registry ID
    NCT03947385
    Conditions
    Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors
    Interventions
    IDE196; Binimetinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-06-28
    Completion
    2027-06-15
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors
    InterventionIDE196; Binimetinib; Crizotinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

    NCT05469113 · start 2019-01-29

    Registered record
    Registry ID
    NCT05469113
    Conditions
    Healthy
    Interventions
    Repaglinide; Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-29
    Completion
    2019-03-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRepaglinide; Selpercatinib
    PhasePhase 1
    Registry statusCompleted

  • Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

    NCT03824002 · start 2017-04-01

    Registered record
    Registry ID
    NCT03824002
    Conditions
    Diabetes Mellitus
    Interventions
    Dulaglutide; Aspart insulin; Glargine; Metformin; Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2018-04-20
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionDulaglutide; Aspart insulin; Glargine; Metformin +1 more
    PhasePhase 4
    Registry statusCompleted

  • Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

    NCT02694263 · start 2016-07

    Registered record
    Registry ID
    NCT02694263
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin; Repaglinide; Pioglitazone; Gliclazide; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07
    Completion
    2018-09-13
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin; Repaglinide; Pioglitazone; Gliclazide +1 more
    PhasePhase 4
    Registry statusCompleted

  • Incretin-based Drugs and Pancreatic Cancer

    NCT02475499 · start 2014-03

    Registered record
    Registry ID
    NCT02475499
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    DPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides; Thiazolidinediones; Alpha-glucosidase inhibitors; Meglitinides
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-04
    Enrolment
    886,172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDPP-4 inhibitors; GLP-1 analogs; Sulfonylureas; Biguanides +3 more
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

    NCT01798706 · start 2013-06

    Registered record
    Registry ID
    NCT01798706
    Conditions
    Type 2 Diabetes
    Interventions
    Lixisenatide (AVE0010); Placebo; Antidiabetic background therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-02
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionLixisenatide (AVE0010); Placebo; Antidiabetic background therapy
    PhasePhase 3
    Registry statusCompleted

  • Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines

    NCT01974544 · start 2013-05

    Registered record
    Registry ID
    NCT01974544
    Conditions
    Type 2 Diabetes
    Interventions
    Best medical treatment; gastric bypass; sleeve gastrectomy; General interventions for all groups: blood presure; General interventions for all groups: dysilipidemia; General interventions for all groups: lifestyle
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-05
    Completion
    2016-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionBest medical treatment; gastric bypass; sleeve gastrectomy; General interventions for all groups: blood presure +2 more
    PhaseNot applicable
    Registry statusUnknown

  • A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

    NCT01709305 · start 2012-11-08

    Registered record
    Registry ID
    NCT01709305
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Metformin; Sitagliptin; Acarbose; Repaglinide; Glimepiride; Gliclazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11-08
    Completion
    2015-04-17
    Enrolment
    5,570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionMetformin; Sitagliptin; Acarbose; Repaglinide +2 more
    PhasePhase 4
    Registry statusCompleted

  • Effects of LRYGB on Pharmacokinetics of Nine CYP Probe Drugs

    NCT03563287 · start 2012-01-27

    Registered record
    Registry ID
    NCT03563287
    Conditions
    Obesity, Morbid; Bariatric Surgery Candidate
    Interventions
    cocktail of nine CYP probe drugs
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01-27
    Completion
    2014-12-10
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity, Morbid; Bariatric Surgery Candidate
    Interventioncocktail of nine CYP probe drugs
    PhaseNot applicable
    Registry statusCompleted